DOCSLIB.ORG

Cannabichromene and Tetrahydrocannabinol Determination in Mouse Blood and Brain by Gas Chromatography–Mass Spectrometry

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cannabichromene and Tetrahydrocannabinol Determination in Mouse Blood and Brain by Gas Chromatography–Mass Spectrometry Wolf_jatsept11.qxd:JATLynneTemplate 7/27/11 10:36 AM Page 1 Journal of Analytical Toxicology, Vol. 35, September 2011 Cannabichromene and Tetrahydrocannabinol Determination in Mouse Blood and Brain by Gas Chromatography–Mass Spectrometry 1 2 2,3 3 Gerald T. DeLong , Carl E. Wolf , Alphonse Poklis , and Aron Lichtman Downloaded from https://academic.oup.com/jat/article/35/7/496/880227 by guest on 24 September 2021 1Occupational and Environmental Health Sciences Division, Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Services, Bethesda, Maryland and Departments of 2Pathology and 3Pharmacology/Toxicology, Virginia Commonwealth University, Richmond, Virginia in marijuana (3). The degree to which these non-THC phyto- Abstract cannabinoids may contribute to marijuana’s overall pharma- Cannabichromene (CBC) is a phytocannabinoid, the second most cological effects, have pharmacological properties of their own, abundant cannabinoid quantitatively in marijuana. CBC has been or modulate the effects of THC remains in question. shown to produce antinociception and anti-inflammatory effects in There are several in vitro and in vivo studies that have uti- rodents. This method is validated for the measurement of THC and lized various mass spectrometry (MS) methods to determine CBC simultaneously after extraction from mouse blood or brain. pharmacokinetic parameters of cannabinoids in humans and Whole brain harvested from mice was homogenized 2:1 (v/w) with laboratory animals (4–7). Often these studies employ methods normal saline. Fifty nanograms of THC-d3 was added to 0.5 mL of that detect THC, 11-OH-THC, and THC-COOH in blood or heparinized mouse blood, brain homogenate, and THC and CBC urine (8). Only a handful of the phytocannabinoids have been fortified blood or brain calibrators, then equilibrated overnight at studied for their pharmacokinetic properties, their possible 5°C. Two milliliters of “ice cold” acetonitrile was added drop-wise while the sample was vortex mixed, and then the sample was modulation of the pharmacokinetics of THC, and ultimately to centrifuged and stored overnight at –30°C. The cannabinoids were correlate these pharmacokinetic parameters to pharmacolog- extracted from the acetonitrile layer with 2 mL of 0.2 N NaOH and ical effects. 4 mL of hexane/ethyl acetate (9:1). The solvent was isolated and Compared to the number of studies that detect cannabi- evaporated to dryness. Trimethylsilyl derivatives were prepared and noids in blood or urine, there are few studies that have uti- then analyzed by gas chromatography–mass spectrometry. lized validated MS methods to measure cannabinoids in brain Linearity in blood and brain of THC and CBC was 2–10,000 ng/mL tissue, which is the site of action for many of the pharmaco- (ng/g). THC and CBC recovery ranged from 56 to 78% in blood logical effects of cannabinoids (9–12). THC and cannabidiol and brain. Precision was demonstrated at 100 ng/mL and 1000 (CBD) have been measured in blood and brain tissue of mice ng/mL with CVs < 15%. The validated method allows for blood to determine possible pharmacokinetic interactions between and brain concentrations of cannabinoids to be quantificated and these cannabinoids (13). In the Varvel et al. study (13), CBD correlated with pharmacological effects produced in mice. significantly increased blood and brain concentrations of THC compared to THC alone and correlated to an increased antinociceptive effect in combination compared to THC Introduction alone. Cannabichromene (CBC) is a phytocannabinoid that has been the second most abundant cannabinoid quantitatively Interest in investigating the pharmacological properties of (behind THC) in some strains of marijuana growing in the Cannabis sativa, or marijuana, is apparent and necessary as United States (14,15). CBC has been shown to produce marijuana is the most commonly used illicit drug in the United antinociception (16) and anti-inflammatory effects in rodents States (1) and remains as one of the most widespread drugs of (17,18). CBC possesses poor affinity to the CB1 receptor (i.e., 9 abuse worldwide. ∆ -Tetrahydrocannabinol (THC) is a proto- Ki value > 10,000 nM) (19). This is consistent with the CB1 typical phytocannabinoid and is recognized as the primary receptor antagonist rimonabant failing to block the tetrad psychoactive constituent in marijuana (2). However, there are activity of CBC, indicating CBC has a non-CB1 receptor mech- an additional 69 phytocannabinoids that have been identified anism of action. In comparison, rimonabant has been reported 496 Reproduction (photocopying) of editorial content of this journal is prohibited without publisher’s permission. Wolf_jatsept11.qxd:JATLynneTemplate 7/27/11 10:37 AM Page 2 Journal of Analytical Toxicology, Vol. 35, September 2011 to have a Ki value of 2 nM and and has been shown to block the Reference materials and reagents tetrad effects of THC and other cannabinoids (20–22). Because CBC was obtained from Organix (Woburn, MA) in its oil rimonabant failed to block the tetrad effects of CBC, the mech- form. CBC stock solutions were prepared in methanol at 1, 5, anism by which CBC elicited tetrad effects has yet to be estab- and 70 µg/mL. THC and THC-d3 were obtained from Ceril- lished. liant (Round Rock, TX) as methanolic solutions at 1 mg/mL Whereas past studies have investigated in vitro metabolites and 100 µg/mL, respectively. THC and THC-d3 stock solutions of CBC via MS (14), there are no reported method validations were prepared in methanol at 1, 10, and 100 µg/mL for THC for measuring CBC after extraction from mouse blood or brain and 1 µg/mL for THC-d3 (internal standard). Standards were tissue following CBC in vivo administration. Furthermore, stored at –30°C when not in use. Deionized water was ASTM there is no reported method validation that simultaneously Type I water from the in-house water system. Hexane, ethyl ac- measures THC and CBC concentrations in blood and brain etate, and acetonitrile were HPLC grade or better, and “ice matrices. The goal of this study was to validate an MS method cold” acetonitrile was stored at –30°C in an ice block when not for the quantification of THC and CBC in mouse blood and in use. Sodium hydroxide (NaOH) was ACS grade. The deriva- brain tissue. Determining the upper limit of linearity (ULOL), tizing agent utililized was RC3 [N,O-bis(trimethylsilyl)- limit of detection (LOD), limit of quantification (LOQ), re- trifluoroacetamide (BSTFA) + 10% trimethylchlorosilane] Downloaded from https://academic.oup.com/jat/article/35/7/496/880227 by guest on 24 September 2021 covery, accuracy, and precision comprised the method valida- (Regis Technologies, Morton Grove, IL). tion. Gas chromatography (GC)–MS equipment Samples were analyzed on a Shimadzu QP2010 GC–MS uti- lizing a splitless injection port and DB-5 column (30 m × 0.25- Materials and Methods mm i.d. × 25-µm film thickness, J&W Scientific, Folsom, CA). The carrier gas was helium, and the injection volume of deriva- Animals tized samples was 1 µL. The injection port temperature and This study utilized naïve (mice not used in any previous transfer line temperatures were maintained at 250°C and studies) male ICR mice (Harlan Laboratories, Dublin, VA) 280°C, respectively. The GC oven temperature program was weighing 20–30 g that were housed six to a cage in the animal 190°C, hold 0.1 min, 30°C/min ramp to 330°C, and hold for 1 care facility maintained at 22 ± 2°C on a 12 h light/dark cycle. min. The ion source and quadrupole temperatures were main- Food and water were available ad libitum, and mice were ac- tained at 260°C and 150°C, respectively. Selective ion moni- climated to the room environment (22 ± 2°C) 24 h before sac- toring mode (SIM) was utilized with a dwell time of 10 ms. Re- rifice. All of our animal work was approved under Virginia tention times were 4.14, 3.98, and 4.12 min for THC, CBC, and Commonwealth University’s Institutional Animal Care and Use THC-d3, respectively (Table I). The following quantification Committee (IACUC #AM10312). Mice were intravenously in- (underlined) and qualitative ions (m/z) identified analytes jected with doses of THC or CBC at 0.3 or 10 mg/kg THC and (Table I): THC, 386, 315, 343; CBC, 303, 246, 271; THC-d3, 389, 3.0 or 100 mg/kg CBC (23). 318, 346. Figure 1 contains the structures of CBC and THC. Calibrator preparation Table I. GC–MS Retention Time and Ions Monitored in THC and CBC calibrators were prepared at 0.5, 1, 2, 5, 10, 20, SIM Mode for THC, CBC, and THC-d 3 50, 100, 250, 500, 1000, 2000, 5000, 7500, and 10,000 ng/mL Rt Ions Monitored (ng/g) in each matrix. The 0.5, 1, 2, 5, 10, 20, and 50 ng/mL Analyte (min) (m/z)* (ng/g) calibrators were prepared from the 1.0 µg/mL THC and CBC standards. The 100, 250, and 500 (ng/g) calibrators were THC 4.14 386, 315, 343 prepared from the 10 µg/mL THC and CBC standards, and the CBC 3.98 303, 246, 271 1000, 2000, 5000, 7500, and 10,000 ng/mL (ng/g) calibrators THC-d3 4.12 389, 318, 346 were prepared from the 100 µg/mL THC and 70 µg/mL CBC standards. Blood and brain calibrators were freshly prepared on * Underlined ions were used for quantification. each day the analysis was performed with freshly harvested mouse blood and brain. Sample collection and extraction procedure Naïve ICR mice were decapitated and whole blood was collected in heparinized tubes (Fisher Scientific, Pittsburgh, PA). Whole brains were harvested and stored on ice until the brain tissue was homog- enized.
Load more

Recommended publications
  • Cannabinoids in Dermatology: a Scoping Review
    Volume 24 Number 6| June 2018| Dermatology Online Journal || Review 24(6): 1 Cannabinoids in dermatology: a scoping review Lauren R M Eagelston1 MD, Nazanin Kuseh Kalani Yazd1 BS, Ravi R Patel2 MD, Hania K Flaten1 BS, Cory A Dunnick3,4 MD, Robert P Dellavalle3,4 MD PhD MSPH Affiliations: 1University of Colorado School of Medicine, Aurora, Colorado, USA, 2Gwinnett Medical Center, Lawrenceville, Georgia, USA, 3University of Colorado School of Medicine, Department of Dermatology, Aurora, Colorado, 4Denver Veterans Affairs Medical Center (VAMC), Department of Dermatology, Denver, Colorado Corresponding Author: Robert P. Dellavalle MD PhD MSPH, Professor of Dermatology, Chief of Dermatology Service, Department of Veteran Affairs Medical Center, 1055 Clermont Rm 6A-105 Mail Stop 16, Denver, CO 80220, Tel: 303.339.8020 x2475, Email: [email protected] Introduction Abstract The cannabinoids are a diverse class of The therapeutic applications of cannabis and pharmacologically active compounds that are cannabinoids are an increasingly conspicuous topic structurally and biologically similar to the primary as de-criminalization and legalization of these products continues to expand. A limited number of psychoactive compound derived from Cannabis cannabinoid compounds have been approved for a sativa -tetrahydrocannabinol (THC), [1-4]. There specific set of conditions. However, the current role are three classes of cannabinoids. Endogenous of cannabinoids for the treatment of dermatologic cannabinoids (endocannabinoids) occur conditions remains to be defined. We conducted a naturally/are constitutively produced in the bodies review of the current literature to determine the of humans and animals [3, 5, 6]. The most well-known applications of cannabinoids for the therapy of members of this class include 2-arachidonoyl- various skin diseases.
    [Show full text]
  • Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System
    International Journal of Molecular Sciences Review Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System Shenglong Zou and Ujendra Kumar * Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC V6T 1Z4, Canada; [email protected] * Correspondence: [email protected]; Tel.: +1-604-827-3660; Fax: +1-604-822-3035 Received: 9 February 2018; Accepted: 11 March 2018; Published: 13 March 2018 Abstract: The biological effects of cannabinoids, the major constituents of the ancient medicinal plant Cannabis sativa (marijuana) are mediated by two members of the G-protein coupled receptor family, cannabinoid receptors 1 (CB1R) and 2. The CB1R is the prominent subtype in the central nervous system (CNS) and has drawn great attention as a potential therapeutic avenue in several pathological conditions, including neuropsychological disorders and neurodegenerative diseases. Furthermore, cannabinoids also modulate signal transduction pathways and exert profound effects at peripheral sites. Although cannabinoids have therapeutic potential, their psychoactive effects have largely limited their use in clinical practice. In this review, we briefly summarized our knowledge of cannabinoids and the endocannabinoid system, focusing on the CB1R and the CNS, with emphasis on recent breakthroughs in the field. We aim to define several potential roles of cannabinoid receptors in the modulation of signaling pathways and in association with several pathophysiological conditions. We believe that the therapeutic significance of cannabinoids is masked by the adverse effects and here alternative strategies are discussed to take therapeutic advantage of cannabinoids. Keywords: cannabinoid; endocannabinoid; receptor; signaling; central nervous system 1. Introduction The plant Cannabis sativa, better known as marijuana, has long been used for medical purpose throughout human history.
    [Show full text]
  • N-Acyl-Dopamines: Novel Synthetic CB1 Cannabinoid-Receptor Ligands
    Biochem. J. (2000) 351, 817–824 (Printed in Great Britain) 817 N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo Tiziana BISOGNO*, Dominique MELCK*, Mikhail Yu. BOBROV†, Natalia M. GRETSKAYA†, Vladimir V. BEZUGLOV†, Luciano DE PETROCELLIS‡ and Vincenzo DI MARZO*1 *Istituto per la Chimica di Molecole di Interesse Biologico, C.N.R., Via Toiano 6, 80072 Arco Felice, Napoli, Italy, †Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, R. A. S., 16/10 Miklukho-Maklaya Str., 117871 Moscow GSP7, Russia, and ‡Istituto di Cibernetica, C.N.R., Via Toiano 6, 80072 Arco Felice, Napoli, Italy We reported previously that synthetic amides of polyunsaturated selectivity for the anandamide transporter over FAAH. AA-DA fatty acids with bioactive amines can result in substances that (0.1–10 µM) did not displace D1 and D2 dopamine-receptor interact with proteins of the endogenous cannabinoid system high-affinity ligands from rat brain membranes, thus suggesting (ECS). Here we synthesized a series of N-acyl-dopamines that this compound has little affinity for these receptors. AA-DA (NADAs) and studied their effects on the anandamide membrane was more potent and efficacious than anandamide as a CB" transporter, the anandamide amidohydrolase (fatty acid amide agonist, as assessed by measuring the stimulatory effect on intra- hydrolase, FAAH) and the two cannabinoid receptor subtypes, cellular Ca#+ mobilization in undifferentiated N18TG2 neuro- CB" and CB#. NADAs competitively inhibited FAAH from blastoma cells. This effect of AA-DA was counteracted by the l µ N18TG2 cells (IC&! 19–100 M), as well as the binding of the CB" antagonist SR141716A.
    [Show full text]
  • The Cannabinoid Receptor Agonist WIN 55,212-2 Attenuates the Effects Induced by Quinolinic Acid in the Rat Striatum
    Neuropharmacology 51 (2006) 1004e1012 www.elsevier.com/locate/neuropharm The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum A. Pintor a, M.T. Tebano a, A. Martire a, R. Grieco a, M. Galluzzo a, M.L. Scattoni b,A.Pe`zzola a, R. Coccurello c, F. Felici a, V. Cuomo d, D. Piomelli e, G. Calamandrei b, P. Popoli a,* a Department of Drug Research and Evaluation, Central Nervous System Pharmacology Division, Istituto Superiore di Sanita`, Viale Regina Elena, 299, 00161 Rome, Italy b Department of Cell Biology and Neuroscience, Istituto Superiore di Sanita`, Viale Regina Elena, 299, 00161 Rome, Italy c Institute of Neuroscience, EBRI Foundation, Rome, Italy d Department of Pharmacology and General Physiology, University ‘‘La Sapienza’’, Rome, Italy e Department of Pharmacology and Center for Drug Discovery, University of California, Irvine, CA, USA Received 7 April 2006; received in revised form 15 May 2006; accepted 16 June 2006 Abstract The ability of CB1 receptors to regulate the release of glutamate in the striatum, together with the finding that, in experimental models of Huntington disease (HD), both endocannabinoid levels and CB1 receptor densities are reduced, has prompted the investigation on the neuropro- tective role of the cannabinoids in HD. Quinolinic acid (QA) is an excitotoxin that, when injected in the rat striatum reproduces many features of HD and that acts by stimulating glutamate outflow. The aim of the present study was to test the ability of the cannabinoid receptor agonist WIN 55,212-2 to prevent the effects induced by QA in the rat striatum.
    [Show full text]
  • Potential Cannabis Antagonists for Marijuana Intoxication
    Central Journal of Pharmacology & Clinical Toxicology Bringing Excellence in Open Access Review Article *Corresponding author Matthew Kagan, M.D., Cedars-Sinai Medical Center, 8730 Alden Drive, Los Angeles, CA 90048, USA, Tel: 310- Potential Cannabis Antagonists 423-3465; Fax: 310.423.8397; Email: Matthew.Kagan@ cshs.org Submitted: 11 October 2018 for Marijuana Intoxication Accepted: 23 October 2018 William W. Ishak, Jonathan Dang, Steven Clevenger, Shaina Published: 25 October 2018 Ganjian, Samantha Cohen, and Matthew Kagan* ISSN: 2333-7079 Cedars-Sinai Medical Center, USA Copyright © 2018 Kagan et al. Abstract OPEN ACCESS Keywords Cannabis use is on the rise leading to the need to address the medical, psychosocial, • Cannabis and economic effects of cannabis intoxication. While effective agents have not yet been • Cannabinoids implemented for the treatment of acute marijuana intoxication, a number of compounds • Antagonist continue to hold promise for treatment of cannabinoid intoxication. Potential therapeutic • Marijuana agents are reviewed with advantages and side effects. Three agents appear to merit • Intoxication further inquiry; most notably Cannabidiol with some evidence of antipsychotic activity • THC and in addition Virodhamine and Tetrahydrocannabivarin with a similar mixed receptor profile. Given the results of this research, continued development of agents acting on cannabinoid receptors with and without peripheral selectivity may lead to an effective treatment for acute cannabinoid intoxication. Much work still remains to develop strategies that will interrupt and reverse the effects of acute marijuana intoxication. ABBREVIATIONS Therapeutic uses of cannabis include chronic pain, loss of appetite, spasticity, and chemotherapy-associated nausea and CBD: Cannabidiol; CBG: Cannabigerol; THCV: vomiting [8]. Recreational cannabis use is on the rise with more Tetrahydrocannabivarin; THC: Tetrahydrocannabinol states approving its use and it is viewed as no different from INTRODUCTION recreational use of alcohol or tobacco [9].
    [Show full text]
  • CBD (Cannabidiol)
    TRANSPORTATION RESEARCH BOARD Driving Toward the Truth - Dispelling the Myths About Cannabis Products February 10, 2021 @NASEMTRB #TRBwebinar PDH Certification The Transportation Research Board has met the standards and Information: requirements of the Registered Continuing Education Providers •1.5 Professional Development Program. Credit earned on completion Hour (PDH) – see follow-up of this program will be reported to email for instructions RCEP. A certificate of completion will •You must attend the entire be issued to participants that have registered and attended the entire webinar to be eligible to receive session. As such, it does not include PDH credits content that may be deemed or •Questions? Contact Reggie construed to be an approval or Gillum at [email protected] endorsement by RCEP. #TRBwebinar Learning Objectives 1. Identify impacts of the Farm Bill on use of THC and CBD products 2. Describe the toxicology of THC and CBD products 3. Discuss how THC and CBD products affect driving performance and crash risk #TRBwebinar TRB Standing Committee on Impairment in Transportation (ACS50) TRB Webinar: Driving Toward the Truth - Dispelling the Myths About Cannabis Products Dr. Barry K. Logan Executive Director, Center for Forensic Science Research and Education (CFSRE); Senior Vice President of Forensic Sciences, and Chief Scientist at NMS Labs Michelle Peace, Ph.D. Associate Professor and PI, Laboratory for Forensic Toxicology Research Department of Forensic Science, Virginia Commonwealth University Dr. Darrin Grondel Vice President,
    [Show full text]
  • Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back
    International Journal of Molecular Sciences Review Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back Osnat Almogi-Hazan * and Reuven Or Laboratory of Immunotherapy and Bone Marrow Transplantation, Hadassah Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel; [email protected] * Correspondence: [email protected] Received: 21 May 2020; Accepted: 19 June 2020; Published: 23 June 2020 Abstract: The Cannabis plant contains numerous components, including cannabinoids and other active molecules. The phyto-cannabinoid activity is mediated by the endocannabinoid system. Cannabinoids affect the nervous system and play significant roles in the regulation of the immune system. While Cannabis is not yet registered as a drug, the potential of cannabinoid-based medicines for the treatment of various conditions has led many countries to authorize their clinical use. However, the data from basic and medical research dedicated to medical Cannabis is currently limited. A variety of pathological conditions involve dysregulation of the immune system. For example, in cancer, immune surveillance and cancer immuno-editing result in immune tolerance. On the other hand, in autoimmune diseases increased immune activity causes tissue damage. Immuno-modulating therapies can regulate the immune system and therefore the immune-regulatory properties of cannabinoids, suggest their use in the therapy of immune related disorders. In this contemporary review, we discuss the roles of the endocannabinoid system in immunity and explore the emerging data about the effects of cannabinoids on the immune response in different pathologies. In addition, we discuss the complexities of using cannabinoid-based treatments in each of these conditions.
    [Show full text]
  • The Cannabinoid WIN 55,212-2 Prevents Neuroendocrine Differentiation of Lncap Prostate Cancer Cells
    OPEN Prostate Cancer and Prostatic Diseases (2016) 19, 248–257 www.nature.com/pcan ORIGINAL ARTICLE The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells C Morell1, A Bort1, D Vara2, A Ramos-Torres1, N Rodríguez-Henche1 and I Díaz-Laviada1 BACKGROUND: Neuroendocrine (NE) differentiation represents a common feature of prostate cancer and is associated with accelerated disease progression and poor clinical outcome. Nowadays, there is no treatment for this aggressive form of prostate cancer. The aim of this study was to determine the influence of the cannabinoid WIN 55,212-2 (WIN, a non-selective cannabinoid CB1 and CB2 receptor agonist) on the NE differentiation of prostate cancer cells. METHODS: NE differentiation of prostate cancer LNCaP cells was induced by serum deprivation or by incubation with interleukin-6, for 6 days. Levels of NE markers and signaling proteins were determined by western blotting. Levels of cannabinoid receptors were determined by quantitative PCR. The involvement of signaling cascades was investigated by pharmacological inhibition and small interfering RNA. RESULTS: The differentiated LNCaP cells exhibited neurite outgrowth, and increased the expression of the typical NE markers neuron-specific enolase and βIII tubulin (βIII Tub). Treatment with 3 μM WIN inhibited NK differentiation of LNCaP cells. The cannabinoid WIN downregulated the PI3K/Akt/mTOR signaling pathway, resulting in NE differentiation inhibition. In addition, an activation of AMP-activated protein kinase (AMPK) was observed in WIN-treated cells, which correlated with a decrease in the NE markers expression. Our results also show that during NE differentiation the expression of cannabinoid receptors CB1 and CB2 dramatically decreases.
    [Show full text]
  • Cannabinoids: Novel Molecules with Significant Clinical Utility
    CANNABINOIDS: NOVEL MOLECULES WITH SIGNIFICANT CLINICAL UTILITY NOEL ROBERT WILLIAMS MD FACOG DIRECTOR OPTIMAL HEALTH ASSOCIATES OKLAHOMA CITY, OKLAHOMA How Did We Get Here? • In November 2012 Tikun Olam, an Israeli medical cannabis facility, announced a new strain of the plant which has only CBD as an active ingredient, and virtually no THC, providing some of the medicinal benefits of cannabis without euphoria. The Researchers said the cannabis plant, enriched with CBD, “can be used for treating diseases like rheumatoid arthritis, colitis, liver inflammation, heart disease and diabetes.” Cannabis CBD like in this article is legally derived from the hemp plant. • CBD is the major non-psychoactive component of Cannabis Sativa (Hemp). Hemp plants are selectively developed and grown to contain high amounts of CBD and very low amounts of the psychoactive component THC found in marijuana. A few CBD oil manufacturers further purify their products to contain high amounts of CBD and no THC. 2014 Farm Bill Terminology • Active Ingredient • Zero THC • Cannabidiol • Isolate • PCR – Phytocannabinoid-Rich • Hemp Oil Extract • “Recommendation” vs. “Prescribed” • Full Spectrum Endocannabinoids (AEA) Phytocannabinoids Full Spectrum & Active Ingredient • CBD – Cannabidiol • A major phytocannabinoid, accounting for as much as 85% of the plant’s extract • CBC – Cannabichromene • Anti-inflammatory & anti-fungal effects have been seen • CBG – Cannabigerol • The parent molecule from which many other cannabinoids are made • CBDV – Cannabidivarin • A homolog of CBD that has been reported to have powerful anti-convulsive effects • CBN – Cannabinol • Sleep & Appetite regulation • Terpenes • Wide spectrum of non-psychoactive molecules that are know to act on neural receptors and neurotransmitters, enhance norepinephrine activity, and potentially increases dopamine activity.
    [Show full text]
  • The Determination of CBD and General Cannabinoid Content In
    No. SSI-HPLC-018 High Performance Liquid Chromatography The Determination of CBD and General Cannabinoid Content in Hemp Oils Using HPLC with UV Detection No. HPLC-018 ■ Introduction Medical marijuana generally possesses high levels of CBD oil is derived as concentrate from CO2 or the therapeutic cannabidiol, CBD, and lower levels butane extraction of hemp, sometimes followed by (generally less than 0.3%) of the psychotropic steam distillation or ethanol distillation for tetrahydrocannabinol, d9-THC. Pain mitigation and purification. The Farm Bill of 2014 distinguishes reduced severity of nausea and seizures are just a hemp from marijuana, yet interpreting the law is few of the therapeutic benefits reported by medical difficult in that “CBD oil” may be classified as cannabis patients. Little has been done to better marijuana. understand the chemistry of benefits from CBD. To complicate matters, there is evidence that a The FDA has issued warning letters to firms that combination of CBD, a host of other minor market unapproved new drugs allegedly contain cannabinoids and a complex array of terpenoids may CBD. As part of these actions, the FDA has be the most beneficial – called the “entourage determined the cannabinoid content of some hemp effect.” CBD-rich oil has become increasingly products and many were found to contain levels of popular and is administered via sublingual drops, gel CBD that are very different from the label claim. It is capsules or as a topical ointment. important to note that such products are not approved by the FDA for the diagnosis, cure, The main source of CBD-rich oil is industrial hemp.
    [Show full text]
  • The Use of Cannabinoids in Animals and Therapeutic Implications for Veterinary Medicine: a Review
    Veterinarni Medicina, 61, 2016 (3): 111–122 Review Article doi: 10.17221/8762-VETMED The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review L. Landa1, A. Sulcova2, P. Gbelec3 1Faculty of Medicine, Masaryk University, Brno, Czech Republic 2Central European Institute of Technology, Masaryk University, Brno, Czech Republic 3Veterinary Hospital and Ambulance AA Vet, Prague, Czech Republic ABSTRACT: Cannabinoids/medical marijuana and their possible therapeutic use have received increased atten- tion in human medicine during the last years. This increased attention is also an issue for veterinarians because particularly companion animal owners now show an increased interest in the use of these compounds in veteri- nary medicine. This review sets out to comprehensively summarise well known facts concerning properties of cannabinoids, their mechanisms of action, role of cannabinoid receptors and their classification. It outlines the main pharmacological effects of cannabinoids in laboratory rodents and it also discusses examples of possible beneficial use in other animal species (ferrets, cats, dogs, monkeys) that have been reported in the scientific lit- erature. Finally, the article deals with the prospective use of cannabinoids in veterinary medicine. We have not intended to review the topic of cannabinoids in an exhaustive manner; rather, our aim was to provide both the scientific community and clinical veterinarians with a brief, concise and understandable overview of the use of cannabinoids in veterinary
    [Show full text]
  • Pharmacodynamics of Cannabinoids
    Open Access Archives of Pharmacy and Pharmaceutical Sciences Review Article Pharmacodynamics of cannabinoids Alexandra Sulcova* ISSN ICCI - International Cannabis and Cannabinoids Institute, Jachymova 26/2, 110 00 Praha, 2639-992X Czech Republic “Pharmacodynamics of cannabinoids “(i.e. a set of biological effects elicited in the *Address for Correspondence: Alexandra Sulcova, M.D, Ph.D, Professor of Pharmacology, living organism by interaction with its biochemical and biophysical functions up to the FCMA, FECNP, FCINP, ICCI - International cellular level) is studied for a long time during both, physiological and pathological Cannabis and Cannabinoids Institute, Jachymova conditions. Cannabinoids received their names according to their natural occurrence 26/2, 110 00 Praha, Czech Republic, Tel: 420 732167678; Email: [email protected] as constituents of Cannabis sativa L. (marijuana). The species was classiied in the “Linnaeus’s Species Plantarum (1753)”, the word “sativa” means things that are Submitted: 12 April 2019 Approved: 07 May 2019 cultivated [1]. For ages, people have used cannabis-based preparations for healing and Published: 08 May 2019 pain suppression until the discovery (in 1897) of aspirin (acetylsalicylic acid) which contemporary medicine uses until today. Chemical investigation of marijuana conirmed Copyright: © 2019 Sulcova A. This is an open access article distributed under the Creative various cannabinoid-type components called cannabinoids (presently estimated at Commons Attribution License, which permits about 150). Regarding their possible pharmacodynamic effects, tetrahydrocannabinol unrestricted use, distribution, and reproduction (THC) and cannabidiol (CBD) are the most explored. The determination of THC structure in any medium, provided the original work is properly cited by means of nuclear magnetic resonance imaging increased sharply the number of professional scientiic reports dealing with the studies of THC pharmacodynamic mechanisms of action [2].
    [Show full text]